Stryka-001 Treatments for Enhanced Muscle Regeneration in FSHD Patients

Presenter
Ryan Wuebbles, PhD.
STRYKA-001

- Enhancer of muscle regeneration through elevated $\alpha 7\beta 1$ Integrin expression
- The enhanced regeneration increases muscle strength and prevents fibrosis after insult
- Stryka-001 is already FDA-approved for another indication and can potentially be fast-tracked
Preclinical FSHD mouse studies using Stryka-001 began February 2018

This project was funded by FSH Society
Acute DUX4 Expression Data

These were the second group to be started and thus the new FSHD mouse cohort just began treatments.
Chronic DUX4 Expression

These studies will conclude in November.
Early Conclusions

- Preliminary data suggests that Stryka-001 therapeutic is a viable stand alone treatment for FSHD patient use.

- Clinical trial planning will begin within 12-months, with an optimistic start in 1.5 years.

- Stryka-001 could potentially be used in combination with other FSHD therapeutics including myostatin inhibitors, immune modulators, and Dux4 inhibiting small molecules or DUX4 gene therapy methodologies with enhanced efficacy.
Developing Transformative Therapeutics & Diagnostics for Life-Threatening Rare Muscle Diseases

Contact: ryan@strykagen.com